The Role of Pelvic Lymph Node Dissection during Radical Prostatectomy in Patients with Gleason Grade 6 Intermediate-Risk Prostate Cancer.

To analyze the benefit of PLND in patients with biopsy Gleason grade≤6, cT≤2b and PSA 10-20ng/ml (main study cohort), as the indication for pelvic lymph node dissection (PLND) during radical prostatectomy (RP) remains uncertain in patients with non-high-risk tumours.

The main study cohort included 1383 patients with low intermediate-risk cancer undergoing RP with or without PLND between 1994 and 2013. Positive lymph node (LN) rates were reported and compared to patients with higher (≥20ng/ml; n=314) and lower (<10ng/ml; n=6861) PSA. Oncological outcome was assessed by Cox-regressions in patients with a minimum follow-up of 5yrs.

In the main study cohort (PSA 10-20ng/ml) PLND was performed in 867 (62.7%) patients with a median number of removed LNs of 11 (IQR 16-6). Positive LNs were detected in 3.3% of these patients. Compared to the main study cohort, patients with preoperatively higher PSA ≥20ng/ml (or lower PSA<10 ng/ml) underwent PLND in 83.8% (32.7%) of the cases with 8.0% (1.8%) showing positive LNs. Median follow-up in the main study cohort was 84.5 months. Biochemical-recurrence occurred in 20.6% of these men. 5-yr and 10-yr BCR-free survival rates were 82.2% and 75.6% for those with and 83.4% and 75.8% for patients without PLND. PLND was not a significant factor influencing BCR-free, metastasis-free or cancer-specific survival in the main study cohort.

Positive LNs are rare in patients with Gleason grade≤6, cT≤2b and PSA 10-20ng/ml. Performing PLND had no statistical influence on oncologic outcome and therefore should be decided upon on an individual basis.

Urology. 2016 Mar 08 [Epub ahead of print]

Philipp Mandel, Maximilian C Kriegmair, Valia Veleva, Georg Salomon, Markus Graefen, Hartwig Huland, Derya Tilki

Martini-Klinik Prostate Cancer Center, University Hospital Hamburg-Eppendorf, Hamburg, Germany; Department of Urology, University Hospital Hamburg-Eppendorf, Hamburg, Germany., Department of Urology, University Hospital Mannheim, Mannheim, Germany., Martini-Klinik Prostate Cancer Center, University Hospital Hamburg-Eppendorf, Hamburg, Germany., Martini-Klinik Prostate Cancer Center, University Hospital Hamburg-Eppendorf, Hamburg, Germany., Martini-Klinik Prostate Cancer Center, University Hospital Hamburg-Eppendorf, Hamburg, Germany., Martini-Klinik Prostate Cancer Center, University Hospital Hamburg-Eppendorf, Hamburg, Germany., Martini-Klinik Prostate Cancer Center, University Hospital Hamburg-Eppendorf, Hamburg, Germany; Department of Urology, University Hospital Hamburg-Eppendorf, Hamburg, Germany. Electronic address: .

E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe